Lineage Cell Therapeutics (LCTX) Shares Outstanding (Weighted Average) (2010 - 2026)

Lineage Cell Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $245.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 8.39% year-over-year to $245.0 million; the trailing twelve-month figure through Mar 2026 stood at $245.0 million (up 8.39% YoY), and the FY2025 full-year result was $41.1 million, up 23.94% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $245.0 million, up from $41.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $245.0 million in Q1 2026, with the low at $33.2 million in Q4 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $171.9 million across 5 years, with a median of $172.7 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 106781.08% — and 2023, when it gained 0.28%.
• Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) stood at $169.8 million in 2022, then climbed by 2.99% to $174.9 million in 2023, then tumbled by 81.04% to $33.2 million in 2024, then advanced by 23.94% to $41.1 million in 2025, then soared by 496.22% to $245.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $245.0 million (Q1 2026), $41.1 million (Q4 2025), and $227.8 million (Q3 2025), per Business Quant data.